Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980611650> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2980611650 endingPage "5628" @default.
- W2980611650 startingPage "5628" @default.
- W2980611650 abstract "Abstract Rafoxanide is used in veterinary medicine for the treatment of fascioliasis. We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported. In this study, we investigated the effects of rafoxanide in multiple myeloma (MM) in vitro and in vivo. We found that rafoxanide inhibited cell proliferation and overcame the protective effect of the bone marrow (BM) microenvironment on MM cells. Rafoxanide induced cell apoptosis by reducing mitochondrial membrane potential (MMP) and regulating the caspase pathway, while having no apparent toxic effect on normal cells. Rafoxanide also inhibited DNA synthesis and caused cell cycle arrest by regulating the cdc25A-degradation pathway. In addition, rafoxanide enhanced the DNA damage response by up-regulating the expression of γ-H2AX. Importantly, as a potent B-Raf V600E inhibitor, rafoxanide could suppress activation of the p38 MAPK pathway. Rafoxanide treatment inhibited tumor growth, with no significant side effects, in an MM mouse xenograft model. Finally, combination of rafoxanide with bortezomib or lenalidomide significantly induced synergistic cytotoxicity in MM cells. Collectively, our results may provide a rationale for use of this drug in MM treatment. This study was supported by grants from the National Natural Science Foundation of China (Nos. 81570190; 81670194 and 81529001). Figure. Figure. Disclosures No relevant conflicts of interest to declare." @default.
- W2980611650 created "2019-10-25" @default.
- W2980611650 creator A5010458663 @default.
- W2980611650 creator A5011273211 @default.
- W2980611650 creator A5024539745 @default.
- W2980611650 creator A5038653609 @default.
- W2980611650 creator A5045909068 @default.
- W2980611650 creator A5055415256 @default.
- W2980611650 creator A5059083216 @default.
- W2980611650 creator A5073693517 @default.
- W2980611650 creator A5083748084 @default.
- W2980611650 date "2018-11-29" @default.
- W2980611650 modified "2023-10-01" @default.
- W2980611650 title "Rafoxanide, an Organohalogen Drug, Triggers Apoptosis and Cell Cycle Arrest in Multiple Myeloma By Enhancing DNA Damage Responses and Suppressing the p38 MAPK Pathway" @default.
- W2980611650 doi "https://doi.org/10.1182/blood-2018-99-113782" @default.
- W2980611650 hasPublicationYear "2018" @default.
- W2980611650 type Work @default.
- W2980611650 sameAs 2980611650 @default.
- W2980611650 citedByCount "0" @default.
- W2980611650 crossrefType "journal-article" @default.
- W2980611650 hasAuthorship W2980611650A5010458663 @default.
- W2980611650 hasAuthorship W2980611650A5011273211 @default.
- W2980611650 hasAuthorship W2980611650A5024539745 @default.
- W2980611650 hasAuthorship W2980611650A5038653609 @default.
- W2980611650 hasAuthorship W2980611650A5045909068 @default.
- W2980611650 hasAuthorship W2980611650A5055415256 @default.
- W2980611650 hasAuthorship W2980611650A5059083216 @default.
- W2980611650 hasAuthorship W2980611650A5073693517 @default.
- W2980611650 hasAuthorship W2980611650A5083748084 @default.
- W2980611650 hasConcept C153911025 @default.
- W2980611650 hasConcept C190283241 @default.
- W2980611650 hasConcept C203014093 @default.
- W2980611650 hasConcept C2776364478 @default.
- W2980611650 hasConcept C2777478702 @default.
- W2980611650 hasConcept C55493867 @default.
- W2980611650 hasConcept C86803240 @default.
- W2980611650 hasConceptScore W2980611650C153911025 @default.
- W2980611650 hasConceptScore W2980611650C190283241 @default.
- W2980611650 hasConceptScore W2980611650C203014093 @default.
- W2980611650 hasConceptScore W2980611650C2776364478 @default.
- W2980611650 hasConceptScore W2980611650C2777478702 @default.
- W2980611650 hasConceptScore W2980611650C55493867 @default.
- W2980611650 hasConceptScore W2980611650C86803240 @default.
- W2980611650 hasIssue "Supplement 1" @default.
- W2980611650 hasLocation W29806116501 @default.
- W2980611650 hasOpenAccess W2980611650 @default.
- W2980611650 hasPrimaryLocation W29806116501 @default.
- W2980611650 hasRelatedWork W1970817319 @default.
- W2980611650 hasRelatedWork W2074366029 @default.
- W2980611650 hasRelatedWork W2075423655 @default.
- W2980611650 hasRelatedWork W2099179340 @default.
- W2980611650 hasRelatedWork W2243925837 @default.
- W2980611650 hasRelatedWork W2356997562 @default.
- W2980611650 hasRelatedWork W2376435852 @default.
- W2980611650 hasRelatedWork W2383734513 @default.
- W2980611650 hasRelatedWork W2389990101 @default.
- W2980611650 hasRelatedWork W3032500323 @default.
- W2980611650 hasVolume "132" @default.
- W2980611650 isParatext "false" @default.
- W2980611650 isRetracted "false" @default.
- W2980611650 magId "2980611650" @default.
- W2980611650 workType "article" @default.